Paradigm Biocapital Advisors LP - Significant Ownership

Signature - Title
David Kim - Chief Operating Officer and Chief Compliance Officer
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Paradigm Biocapital Advisors LP.

Significant Ownership of Paradigm Biocapital Advisors LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
OLMA Olema Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share 9.99% $33.5M 7.43M Paradigm BioCapital Advisors LP Dec 31, 2024
JANX Janux Therapeutics, Inc. Common Stock, $0.001 par value per share 6% $112M 3.52M Paradigm BioCapital Advisors LP Dec 31, 2024
LENZ LENZ Therapeutics, Inc. Common Stock, $0.00001 par value per share 5.2% $34.9M 1.42M Paradigm BioCapital Advisors LP Mar 20, 2025
MRUS Merus N.V. Common Shares, EUR0.09 nominal value per share 5.1% $169M 3.55M Paradigm BioCapital Advisors LP Apr 3, 2025
EWTX Edgewise Therapeutics, Inc. Common Stock, $0.0001 par value per share 5% $133M 4.74M Paradigm BioCapital Advisors LP Jan 27, 2025
COGT Cogent Biosciences, Inc. Common Stock, $0.001 par value per share 5% $40.5M 5.56M Paradigm BioCapital Advisors LP Feb 5, 2025
KURA Kura Oncology, Inc. Common Stock, $0.0001 par value per share 0% $0 0 Paradigm BioCapital Advisors LP Dec 31, 2024

Schedules 13D/G Reported by Paradigm Biocapital Advisors LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.